BEHANDLUNG MULTIPLER SKLEROSE MIT LAQUINIMOD

Patent europeic · EP2442651 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP2442651
Numer da la dumonda
EP10789873
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
18-06-2010
Publitgà
25-04-2012
Concedì
29-07-2015
Stritgà
30-06-2018
Motiv
Taxa annuala betg pajada
Classas IPC
A61P 25/00 (2006.01)
A01N 43/42 (2006.01)
A61K 31/4704 (2006.01)
A61K 31/136 (2006.01)
A61K 38/16 (2006.01)
A61K 45/06 (2006.01)
Prioritad
US 269070 P 19.06.2009
Dumonda PCT
PCT/US2010/001759 18.06.2010
Publicaziun PCT
WO2010/147665 23.12.2010
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 23-01-2019

    Stritgà, taxa betg pajada

    Published in Swissreg on 23.01.2019

  2. 28-10-2015

    Represchentant inscrit

    Representative
    Bugnion S.A., Case postale 375, 1211 Genève 12 - Champel

    Published in Swissreg on 28.10.2015

  3. 29-07-2015

    Concedì

    Published in Swissreg on 29.07.2015

Partidas

Possessur

Teva Pharmaceutical Industries Ltd.

5 Basel Street P.O. Box 3190, 49131 Petah Tiqva, IL

Represchentant

Bugnion SA

Bugnion S.A.

Case postale 375, 1211 Genève 12 - Champel

Inventur

TARCIC, Nora

Modiin, IL

BAR-ZOHAR, Dan

52365 Ramat-Gan, IL

KOFLER, Dina

Kadima-Zoran, IL

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.